MedNation Past Earnings Performance

Past criteria checks 0/6

MedNation's earnings have been declining at an average annual rate of -26.8%, while the Healthcare industry saw earnings growing at 4.4% annually. Revenues have been declining at an average rate of 7.5% per year.

Key information

-26.8%

Earnings growth rate

-26.8%

EPS growth rate

Healthcare Industry Growth15.7%
Revenue growth rate-7.5%
Return on equity-22.0%
Net Margin-4.9%
Last Earnings Update30 Jun 2023

Recent past performance updates

Recent updates

The Return Trends At MedNation (FRA:EIF) Look Promising

Mar 06
The Return Trends At MedNation (FRA:EIF) Look Promising

Investors Still Aren't Entirely Convinced By MedNation AG's (FRA:EIF) Revenues Despite 31% Price Jump

Jan 03
Investors Still Aren't Entirely Convinced By MedNation AG's (FRA:EIF) Revenues Despite 31% Price Jump

These 4 Measures Indicate That MedNation (FRA:EIF) Is Using Debt Extensively

Dec 23
These 4 Measures Indicate That MedNation (FRA:EIF) Is Using Debt Extensively

MedNation (FRA:EIF) Is Looking To Continue Growing Its Returns On Capital

Oct 10
MedNation (FRA:EIF) Is Looking To Continue Growing Its Returns On Capital

MedNation AG's (FRA:EIF) 32% Dip In Price Shows Sentiment Is Matching Earnings

Jul 29
MedNation AG's (FRA:EIF) 32% Dip In Price Shows Sentiment Is Matching Earnings

Returns On Capital Are Showing Encouraging Signs At MedNation (FRA:EIF)

Jun 29
Returns On Capital Are Showing Encouraging Signs At MedNation (FRA:EIF)

Returns Are Gaining Momentum At Eifelhöhen-Klinik (FRA:EIF)

Dec 03
Returns Are Gaining Momentum At Eifelhöhen-Klinik (FRA:EIF)

These 4 Measures Indicate That Eifelhöhen-Klinik (FRA:EIF) Is Using Debt Extensively

Oct 09
These 4 Measures Indicate That Eifelhöhen-Klinik (FRA:EIF) Is Using Debt Extensively

Is Eifelhöhen-Klinik (FRA:EIF) Using Debt Sensibly?

Jun 03
Is Eifelhöhen-Klinik (FRA:EIF) Using Debt Sensibly?

Is Eifelhöhen-Klinik (FRA:EIF) Using Debt In A Risky Way?

Oct 16
Is Eifelhöhen-Klinik (FRA:EIF) Using Debt In A Risky Way?

Is Eifelhöhen-Klinik (FRA:EIF) Using Too Much Debt?

Jun 07
Is Eifelhöhen-Klinik (FRA:EIF) Using Too Much Debt?

Will Eifelhöhen-Klinik's (FRA:EIF) Growth In ROCE Persist?

Feb 22
Will Eifelhöhen-Klinik's (FRA:EIF) Growth In ROCE Persist?

Revenue & Expenses Breakdown
Beta

How MedNation makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:EIF Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2340-210
31 Mar 2339-210
31 Dec 2238-210
30 Sep 2238-300
30 Jun 2239-300
31 Mar 2238-400
31 Dec 2137-400
30 Sep 2136-300
30 Jun 2135-200
31 Mar 2136-200
31 Dec 2036-100
30 Sep 2039-200
30 Jun 2042-200
31 Mar 2046-100
31 Dec 1950-100
30 Sep 1950-130
30 Jun 1951-150
31 Mar 1951-150
31 Dec 1851-150
30 Sep 1850-150
30 Jun 1849050
31 Mar 1849050
31 Dec 1748050
30 Sep 1748050
30 Jun 1748-140
31 Mar 1749240
31 Dec 1649540
30 Sep 1649540
30 Jun 1649530
31 Mar 1648230
31 Dec 1547-130
30 Sep 1546-130
30 Jun 1544-130
31 Mar 1544-130
31 Dec 1443030
30 Sep 1442030
30 Jun 1442130
31 Mar 1441030
31 Dec 1340030
30 Sep 1339030
30 Jun 1338030

Quality Earnings: EIF is currently unprofitable.

Growing Profit Margin: EIF is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: EIF is unprofitable, and losses have increased over the past 5 years at a rate of 26.8% per year.

Accelerating Growth: Unable to compare EIF's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EIF is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-7.5%).


Return on Equity

High ROE: EIF has a negative Return on Equity (-22%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.